GODEX + Placebo

Phase 3Recruiting
2 views this week 0 watching Active
Interest: 47/100
47
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Alcoholic Fatty Liver Disease

Conditions

Non-Alcoholic Fatty Liver Disease

Trial Timeline

Sep 25, 2023 → Feb 26, 2027

About GODEX + Placebo

GODEX + Placebo is a phase 3 stage product being developed by Celltrion for Non-Alcoholic Fatty Liver Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06152991. Target conditions include Non-Alcoholic Fatty Liver Disease.

What happened to similar drugs?

0 of 3 similar drugs in Non-Alcoholic Fatty Liver Disease were approved

Approved (0) Terminated (0) Active (3)
🔄Semaglutide + PlaceboNovo NordiskPhase 3
🔄Placebo + ResmetiromMadrigal PharmaceuticalsPhase 3
🔄ResmetiromMadrigal PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06152991Phase 3Recruiting

Competing Products

20 competing products in Non-Alcoholic Fatty Liver Disease

See all competitors